NP_004324.2
[Other Products]
NCBI GenBank Nucleotide #
|
[Other Products]
UniProt Primary Accession #
|
[Other Products]
UniProt Secondary Accession #
UniProt Related Accession #
NCBI Official Full Name
serine/threonine-protein kinase B-raf
NCBI Official Synonym Full Names
B-Raf proto-oncogene, serine/threonine kinase
NCBI Protein Information
serine/threonine-protein kinase B-raf
UniProt Protein Name
Serine/threonine-protein kinase B-raf
UniProt Synonym Protein Names
Proto-oncogene B-Raf; p94; v-Raf murine sarcoma viral oncogene homolog B1
UniProt Synonym Gene Names
UniProt Entry Name
BRAF_HUMAN
NCBI Summary for BRAF
This gene encodes a protein belonging to the raf/mil family of serine/threonine protein kinases. This protein plays a role in regulating the MAP kinase/ERKs signaling pathway, which affects cell division, differentiation, and secretion. Mutations in this gene are associated with cardiofaciocutaneous syndrome, a disease characterized by heart defects, mental retardation and a distinctive facial appearance. Mutations in this gene have also been associated with various cancers, including non-Hodgkin lymphoma, colorectal cancer, malignant melanoma, thyroid carcinoma, non-small cell lung carcinoma, and adenocarcinoma of lung. A pseudogene, which is located on chromosome X, has been identified for this gene. [provided by RefSeq, Jul 2008]
UniProt Comments for BRAF
BRAF: a tyrosine kinase-like kinase of the RAF family. Involved in the transduction of mitogenic signals from the cell membrane to the nucleus. May play a role in the postsynaptic responses of hippocampal neuron. Frequently mutated in thyroid cancers, skin melanomas and at lower frequency in a wide range of human cancers. An activating mutation, mimicking phosphorylation of the activation loop, is seen in 60% of malignant melanoma samples. Raf mutations are generally exclusive to Ras activating mutations. Activating mutations are also seen in ~10% of colorectal cancers, in lung cancers and gliomas, and at a lower rate in several other tumors. Inactivating mutations are also seen and may result in activation of c-Raf and Erk. Mutations in B-Raf, MEK1 and MEK2 also associated with cardiofaciocutaneous syndrome, displaying morphological, cardiac and mental defects. Approved Inhibitor: Nexavar/Sorafenib.
Protein type: EC 2.7.11.1; Protein kinase, Ser/Thr (non-receptor); Oncoprotein; Protein kinase, TKL; Kinase, protein; TKL group; RAF family
Chromosomal Location of Human Ortholog: 7q34
Cellular Component: neuron projection; mitochondrion; plasma membrane; nucleus; cytosol
Molecular Function: small GTPase binding; protein serine/threonine kinase activity; identical protein binding; protein binding; MAP kinase kinase kinase activity; mitogen-activated protein kinase kinase binding; protein heterodimerization activity; calcium ion binding; ATP binding; protein kinase activity
Biological Process: axon guidance; response to cAMP; CD4-positive, alpha beta T cell differentiation; nerve growth factor receptor signaling pathway; activation of MAPKK activity; protein heterooligomerization; somatic stem cell maintenance; glucose transport; protein amino acid phosphorylation; synaptic transmission; myeloid progenitor cell differentiation; small GTPase mediated signal transduction; positive regulation of stress fiber formation; visual learning; negative regulation of neuron apoptosis; epidermal growth factor receptor signaling pathway; positive T cell selection; positive regulation of axon regeneration; fibroblast growth factor receptor signaling pathway; MAPKKK cascade; positive regulation of peptidyl-serine phosphorylation; regulation of cell proliferation; organ morphogenesis; Ras protein signal transduction; insulin receptor signaling pathway; innate immune response; positive regulation of axonogenesis; vascular endothelial growth factor receptor signaling pathway; negative regulation of apoptosis
Disease: Noonan Syndrome 1; Noonan Syndrome 7; Lung Cancer; Cardiofaciocutaneous Syndrome 1; Leopard Syndrome 3
Product References and Citations for anti-BRAF antibody
Stephens R.M.,et al.Mol. Cell. Biol. 12:3733-3742(1992).
Albert S.,et al.Submitted (JAN-2004) to the EMBL/GenBank/DDBJ databases.
Scherer S.W.,et al.Science 300:767-772(2003).
Hillier L.W.,et al.Nature 424:157-164(2003).
Eychene A.,et al.Oncogene 7:1657-1660(1992).
Research Articles on BRAF
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice. It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
Products associated with anti-BRAF antibody
Pathways associated with anti-BRAF antibody
Diseases associated with anti-BRAF antibody
Organs/Tissues associated with anti-BRAF antibody
|